Devonian Health Group announces the publication of positive results of the Purgenesis® Anti-aging Care clinical study in the Journal of Cosmetic Dermatology

For immediate release

Devonian Health Group announces the publication of positive results of the Purgenesis® Anti-aging Care clinical study in the Journal of Cosmetic Dermatology.


QUEBEC, August 28, 2019 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announced today the publication of positive results from the comparative clinical study on Purgenesis® Anti-aging Care in the management of lateral canthal lines (Crow’s feet).

Published in the peer-reviewed Journal of Cosmetic Dermatology1 and titled ‘‘Comparison of topical antiaging creams in the management of lateral canthal lines’’, the article describes results from a clinical study comparing the efficacy of Purgenesis® antiaging creams ( Day cream, Eye Cream and Night Cream) to Prevage® (Eye Lotion, Day Cream and Night Cream) and to LaMer® ( Eye Balm, Crème de la Mer and Night Cream) in the management of lateral canthal lines.

This single-center, single-blind, parallel-design clinical study enrolled 72 healthy female volunteers, aged 35 to 72 years, with fine-to-moderate wrinkles in the lateral canthal areas (crow feet). Assessments were conducted over 28 days and included skin hydration, cutaneous elasticity, profilometry (anti-wrinkle effect) and satisfaction survey (volunteers’ perception of their treatment).  Results showed that volunteers using the Purgenesis® Anti-aging Care line experienced more statistically significant improvements in objective measures than seen with the two other product lines. These improvements include skin hydration, extensibility, fatigability, firmness, and effects on wrinkles (total number, area and total length of wrinkles).  All treatments were well tolerated by the majority of the participants.

What intrigues me about Purgenesis® is that it’s a Canadian made, naturally sourced botanical, backed by science. When I recommend it to patients, I emphasize the fact that it is an anti-aging treatment system, not just a moisturizer. I am very impressed that Devonian had the faith in their product to test it head-to-head against leading brands. The results were quite interesting, with Purgenesis® coming out on top.”, said Dr. Julia M. Carroll BSC, MD, FRCP, Director and Co-Founder of Compass Dermatology; Director of Dermatology, The Medcan Clinic. Toronto, Ontario.

“Effective antioxidants are a cornerstone of the skin care regimens I recommend to my patients. Purgenesis® and its primary active ingredient, R-Spinosome®, outperformed two existing market-leading antioxidants. The properties documented in this paper clearly demonstrate that Purgenesis® is an excellent choice for people looking for a cosmetically elegant, total antioxidant solution for the face, neck and eyes.”, said Dr. Sam Hanna MD, FAAD, DABD, Medical Director, Dermatology on Bloor; President, Toronto Dermatology Society, Toronto, Ontario.

“We are very pleased to announce this scientific publication describing the efficacy of Purgenesis® Anti-aging Care line. The data from this clinical study highlights the efficacy and faster onset of action of Purgenesis®, as seen by a statistical reduction of the total number of wrinkles after only one day of treatment, compared to Prevage® and LaMer®. We look forward to evaluate the longer-term effects of our products in a future clinical trial.”, says Devonian’s President & CEO, Dr. Andre P. Boulet, PhD.

 “With this recent publication, Purgenesis® is well positioned to respond to the increasing and discerning demand for evidence-based skincare products. Purgenesis® is exclusively available from dermatologists, plastic surgeons and medical spas, and for good reason. Who else but medically trained skin care experts can appreciate the decades of research that has given life to the active complex R-Spinasome®. This is what forms the basis of Purgenesis® and the reason why our science-based, clinically proven formulations are chosen by experts as the daily skincare solution for women and men of all skin types.”, says Sybil Dahan, President of Altius Healthcare, Devonian’s Commercial Division,


About Purgenesis® Anti-aging Care treatment

Purgenesis® Anti-aging Care treatment has three components: a day cream, a night cream and an eye cream. These creams contain R-Spinasome®, a complex that is an active structure with anti-oxidant properties. The structure of this complex is critical to its function as an anti-oxidant, enabling it to capture and dissipate noxious energy generated by Reactive Oxygen Species (ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this dynamism and capacity to regenerate that provides R-Spinasome® with unprecedented, long-lasting antioxidant activity. Purgenesis® Anti-aging treatment is patent protected in Japan, Canada, United States and Europe (#JP 5952261; #CDN 2,699,6765; #US 13/261,472, #EUR 11 768 299.7). The product has been recognized by the Canadian Dermatology Association’s Skin Health Program™.


About Devonian

Devonian Health Group Inc. is a late stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.  Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).

For more information, visit

About Altius Healthcare Inc.

Based in Concord, Ontario, Altius Healthcare is a specialty pharmaceutical company with a primary focus of acquiring and in-licensing safe and innovative medicines and healthcare products designed to help people of all ages live healthier lives. Altius then leverages its expertise in the commercialisation activities required to successfully launch and distribute these medicines in Canada. The team’s diverse experience and expertise draws from nearly 40 years of producing, importing, marketing and distributing branded and generic medicines.

For more information, visit


Carroll, JM; Guenther, LC; Hanna, S and N Boucher, Comparison of topical antiaging creams in the management of lateral canthal lines. J. Cosmet. Dermatol. 2019; 00:1-11

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Dr. André P. Boulet, PhD
President and Chief Executive Officer
Devonian Health Group Inc.
Telephone: (514) 248-7509